Researchers to begin Phase II trials on new hepatitis B vaccine

07/27/2005 | BiotechEast

Chinese researchers plan to begin Phase II trials soon on a new type of vaccine for hepatitis B, using a protein to teach an immune response instead of the usual treatment with interferon. The protein vaccine has been found to change the immune system's tolerance so it can produce endogenesis cells to attack the virus.

View Full Article in:

BiotechEast

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ